- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01607710
Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI) (fMRI)
September 4, 2014 updated by: Hartford Hospital
The investigators are seeking to locate the brain regions of interest in generalized anxiety disorder (GAD) using both structural (sMRI) and functional magnetic resonance imaging (fMRI).
The MRI will be used to measure changes in blood flow in the brain while at rest and while completing tasks designed to elicit symptoms of anxiety.
Results from a nonclinical control group and a GAD group will be compared to determine whether they exhibit different areas of brain activity during the tasks.
Study Overview
Status
Completed
Conditions
Detailed Description
20 healthy controls and 20 participants with GAD will be recruited.
Each participant will undergo an MRI session that will last approximately 2 hours.
The structural MRI will be used when the participant is at rest.
During the functional MRI (fMRI), a computer screen inside the scanner will display four tasks the participant must complete: (1)Gambling Task, (2)Risk & Ambiguity Task, (3)Reading Emotion from the Eyes (REE) Task, and (4)Emotional Counting Task.
Study Type
Observational
Enrollment (Actual)
55
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Connecticut
-
Hartford, Connecticut, United States, 06105
- Hartford Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Residents of the Greater Hartford Connecticut area.
Description
Generalized Anxiety Disorder(GAD)Group:
Inclusion Criteria:
- Clinical diagnosis of Generalized Anxiety Disorder
- Hamilton Anxiety Rating Scale score of 18 or higher
- Hamilton Rating Scale for Depression score of 17 or less
- Fluency in English
- Capacity to understand the nature of the study and willingness to sign informed consent for
Exclusion Criteria:
- History of epilepsy or head trauma (Loss of consciousness>5 minutes) with the past 6 months
- Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis or brain surgery
- A review of patient medications by the study physician indicates an increased risk of seizure
- An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
- Substance use disorder or posttraumatic stress disorder (PTSD) within the past 6 months
- Lifetime bipolar disorder, obsessive-compulsive disorder (OCD), psychotic disorder, mental retardation, or pervasive development disorder
- Any psychotic features, including dementia or delirium
- Medication change within past 3 months
- Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months
- Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study
- Any contraindication for participation in MRI scan
Nonclinical Control Group:
Inclusion Criteria:
- Absence of any psychiatric diagnosis
Exclusion Criteria:
- History of epilepsy or head trauma (Loss of Consciousness>5 minutes) with the past 6 months
- Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis or brain surgery
- A review of patient medications by the study physician indicates an increased risk of seizure
- An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency
- Substance use disorder or PTSD within the past 6 months
- Lifetime bipolar disorder, OCD, psychotic disorder, mental retardation, or pervasive development disorder
- Any psychotic features, including dementia or delirium
- Medication change within past 3 months
- Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months
- Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study
- Any contraindication for participation in MRI scan
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Generalized Anxiety Disorder
The group of participants diagnosed with generalized anxiety disorder.
|
Nonclinical Control Group
The comparison group of participants with no psychiatric diagnoses.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brain activation while undergoing the fMRI
Time Frame: Throughout the fMRI
|
Main effects for each condition will be calculated to elucidate brain activations relevant to the tasks.
Random effect 2 sample t-tests will assess group differences (i.e., GAD patients vs. healthy controls) to identify regions that demonstrate hyperactivation in patients.
|
Throughout the fMRI
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2012
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
May 25, 2012
First Submitted That Met QC Criteria
May 29, 2012
First Posted (Estimate)
May 30, 2012
Study Record Updates
Last Update Posted (Estimate)
September 5, 2014
Last Update Submitted That Met QC Criteria
September 4, 2014
Last Verified
March 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIEF003523.2
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Xijing HospitalRecruitingGeneralized Anxiety DisorderChina
-
Sichuan Jishengtang Pharmaceutical Co., Ltd.Not yet recruitingGeneralized Anxiety Disorder
-
Hospital de Clinicas de Porto AlegreRecruitingGeneralized Anxiety DisorderBrazil
-
University of California, Los AngelesMedical University of South Carolina; Massachusetts General HospitalRecruitingGeneralized Anxiety DisorderUnited States
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedGeneralized Anxiety DisorderCanada
-
Laureate Institute for Brain Research, Inc.National Institute of Mental Health (NIMH)CompletedGeneralized Anxiety DisorderUnited States
-
The Canadian College of Naturopathic MedicineMassachusetts General Hospital; McGill University; Mitacs; Ekhagastiftelsen; Netherlands... and other collaboratorsActive, not recruitingGeneralized Anxiety DisorderCanada